Jonathan Chang
Stock Analyst at Leerink Partners
(0.62)
# 3,922
Out of 4,944 analysts
88
Total ratings
29.73%
Success rate
-19.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Market Perform | $21 → $3 | $5.09 | -41.06% | 10 | Jul 22, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $35.63 | +110.50% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $22.67 | +19.10% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $33.00 | +124.24% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $7.85 | +40.13% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $11.62 | +338.90% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $4.45 | +1,585.39% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $7.35 | +580.27% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $36.07 | -16.83% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.66 | +622.89% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $350 | $6.81 | +5,039.50% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $6.10 | +326.23% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.08 | +3,736.32% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $6.49 | +331.43% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $7.72 | +586.53% | 7 | Aug 5, 2021 |
Replimune Group
Jul 22, 2025
Downgrades: Market Perform
Price Target: $21 → $3
Current: $5.09
Upside: -41.06%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $35.63
Upside: +110.50%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $22.67
Upside: +19.10%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $33.00
Upside: +124.24%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $7.85
Upside: +40.13%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $11.62
Upside: +338.90%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $4.45
Upside: +1,585.39%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $7.35
Upside: +580.27%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $36.07
Upside: -16.83%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.66
Upside: +622.89%
Aug 9, 2022
Maintains: Outperform
Price Target: $325 → $350
Current: $6.81
Upside: +5,039.50%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $6.10
Upside: +326.23%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.08
Upside: +3,736.32%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $6.49
Upside: +331.43%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $7.72
Upside: +586.53%